header image

Noticias Recientes

Australia's Therapeutic Goods Administration approves Octapharma’s human cell line recombinant FVIII Nuwiq®

07.11.2014

Lachen, Switzerland, November 7th, 2014: Octapharma is pleased to announce that Australia's Therapeutic Goods Administration has approved Octapharma’s human cell line recombinant FVIII Nuwiq® for the treatment and prophylaxis of...

Health Canada approves Octapharma’s new generation recombinant FVIII (Nuwiq®) for all age groups in haemophilia A

05.11.2014

Lachen, Switzerland, November 5th, 2014: Octapharma Canada announces that Health Canada has approved Nuwiq® (recombinant FVIII) for treatment and prophylaxis of bleeding in patients of all ages suffering with haemophilia A...

European Commission publishes approval of Octapharma’s human cell line recombinant FVIII (Nuwiq®) across all age groups in haemophilia A

05.08.2014

Lachen, Switzerland, August 5th, 2014: The European Commission has published approval of Octapharma’s Nuwiq® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with haemophilia A (congenital...

Octapharma USA Announces FDA Approval of octagam® 10%, expanding its Immune Globulin Therapy Portfolio

17.07.2014

LACHEN, Switzerland, July 17th, 2014: Octapharma USA announce the U.S. Food and Drug Administration (FDA) has approved octagam® 10% [Immune Globulin Intravenous (Human) 10% 100 mg/mL Liquid Preparation] for the treatment of...

Octapharma sponsors symposium “Spotlight on the human factor: building a foundation for the future of haemophilia A management" at 2014 WFH World Congress in Melbourne, Australia

27.05.2014

LACHEN, Switzerland, May 27th, 2014: Octapharma sponsored the symposium "Spotlight on the human factor: building a foundation for the future of haemophilia A management" during the World Federation of Hemophilia (WFH)...

European Medicines Agency (EMA) adopts positive opinion on Octapharma’s human cell line recombinant human FVIII (Nuwiq®) in children and adults with haemophilia A

23.05.2014

Lachen, Switzerland, May 23rd, 2014 – Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing...